Bone Therapeutics' allogeneic osteoblastic product to enter clinic for the treatment of delayed union fractures (press release)
BONE THERAPEUTICS, the leading biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, announces today that it has received clearance from the Competent Authorities in Belgium and the UK for a phase I/IIa trial with its allogeneic cell therapy product ALLOB® for the treatment of delayed union fractures.
ALLOB® is an allogeneic[1], osteoblastic (i.e. bone-forming) cell therapy product. ALLOB® has already shown safety an...
